Cenerimod is Actelion's second selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator, it is both potent and orally active.
Cenerimod blocks the egress of lymphocytes from lymphoid organs thereby reducing the availability of circulating effector T and B cells that can invade target organs. This pharmacodynamic effect is sustained with continued daily oral dosing and is reversible upon drug discontinuation.
Cenerimod is being evaluated in a Phase II prospective, multicenter, multinational, randomized, double-blind, placebo-controlled, dose-response study to investigate the biological activity, safety, and tolerability of cenerimod in adult subjects with systemic lupus erythematosus (SLE). Approximately 64 subjects will be enrolled to receive either 0.5, 1, 2 or 4 mg/day of cenerimod over a treatment period of 12 weeks. The study is being conducted at approximately 20 sites and is expected to last around 20 months.
In the Phase I program, cenerimod showed marked and sustained lymphocyte lowering effects, supporting further exploration in patients.
2015 – Initiation of Phase II clinical development in systemic lupus erythematosus
Kappos L et al. N Engl J Med. 362(5):387-401, 2010
Borchers AT, et al. Autoimmun Rev. 2010 Mar;9(5):A277-87.
Pons-Estel GJ, et al. Semin Arthritis Rheum. 2010 Feb;39(4):257-68.
Govoni M, et al. Lupus. 2006;15:110-113.
Rahman A, Isenberg DA. N Engl J Med. 2008; 358:929-39.
Abu-Shakra M, et al. J Rheumatol 1995;22(7):1259-64.